MagIA Diagnostics SAS of Grenoble at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

MagIA Diagnostics SAS

Cime Nanotech, 3 Parvis Louis Néel, 38000 Grenoble
Telephone +33 4 56529431

This company is co-exhibitor of
Business France SA

Hall map

MEDICA 2018 hall map (Hall 3): stand H74

Fairground map

MEDICA 2018 fairground map: Hall 3




Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

  • 03  Diagnostic Tests
  • 03.05  Infectious immunology testing
  • 03.05.03  Other infectious immunology testing

Other infectious immunology testing

About us

Company details

MagIA Diagnostics develops a highly innovative and generic Point of Care technology allowing for easy transfer of any immunoassay onto a portable system. Based on our patented generic no-wash immunoassay technique emerging from 15 years of research, MagIA diagnostics unique value proposition is to bring lab immunoassays directly to the patient.

 Syndromic infection disease screening kits : The growing challenges of pandemic risk management and personalised health approaches drive the need for decentralised diagnostic solutions. MagIA diagnostics’ highly sensitive infectious disease screening platform integrates a multi-parameter lab-performant immuno-analysis on a single disposable chip. We develop a unique panel of infectious diseases assay chips, starting with a Hepatitis B and a combined HIV / Hepatitis screening panel to enhance access to care.

 OEM manufacturer : At MagIA diagnostics, we believe in accessible Point-of-Care diagnostics. To make it available to everyone, we are also developing a business to business approach: as companies providing immunologic diagnostic solutions (14B$ human immunodiagnostic market) are pushing to bring their products closer to the patients, we are offering them access to our generic Point-of-Care platform. It preserves the laboratory sensitivity while significantly reducing test time (15 min) and sample volume (5 - 10 µl), offering a unique and highly relevant solution for all immunoassay applications.

More Less